Parkinson's Disease
US PARKINSON'S DISEASE PARTNER
EUROPEAN PARTNER
EU PARKINSON'S DISEASE PARTNER
INTERNATIONAL PARKINSON'S DISEASE PARTNER
An Introduction to Parkinson's Disease
Parkinson’s disease (PD), the most common movement disorder, is characterized by dopamine deficiency and motor symptoms, such as tremor, rigidity, bradykinesia and impaired balance; non-motor symptoms are increasingly being recognized as important too. Despite advances in our understanding of PD by functional genetics, brain imaging and biomarker detection, it remains incurable. While levodopa remains the mainstay of therapy, other treatments include levodopa plus carbidopa (oral/gel infusion), dopamine agonists, MAO-B and COMT inhibitors, anticholinergics and amantadine. Latest approvals include opicapone, a COMT inhibitor, and istradefylline, an adenosine A2A antagonist; both boost the effect of levodopa for better symptom control. Investigational approaches include disease-modifying therapies targeting α-synuclein and its pathways, immunotherapies, stem-cell therapy and non-pharmacological interventions targeting motor symptoms, including gene therapy and adaptive deep-brain stimulation.
Browse video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and peer-reviewed articles from the journal portfolio. This is complimented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Our supporting partners do not constitute an endorsement of the content on this page.
What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career clinicians ready to think beyond the bedside and explore the business of medicine.
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
The 2025 Annual Meeting of the American Academy of Neurology in San Diego brought together over 14,500 neurology professionals from 110 countries and all 50 US states, alongside more than 300 exhibiting companies. It was a week filled with inspiring science, learning, and global collaboration—all in support of advancing brain health for all. Among the many highlights were the late-breaking abstracts, showcasing some of the most exciting developments in neurology. From this impressive selection, we’ve chosen five standout presentations that reflect the innovation and momentum seen throughout the meeting.
The Food and Drug Administration (FDA) has approved ONAPGO™ (apomorphine hydrochloride) sublingual film for the treatment of “off” episodes in Parkinson’s disease (PD), providing patients with a new, on-demand therapy to rapidly alleviate motor symptoms when standard medications wear off.
As we move through 2025, touchNEUROLOGY remains committed to sharing the latest developments in Parkinson’s disease (PD). Our society partners at Parkinson’s Europe have outlined three key hopes for the year ahead—each representing a crucial step toward better support, understanding and treatment for the Parkinson’s community.
As 2024 draws to a close, we’re celebrating a fantastic year of content.
In this episode, we’re joined by Bradley Love, Professor of Cognitive and Decision Sciences at UCL, ELLIS fellow, and creator of BrainGPT. We discuss how this large language model is poised to assist researchers in advancing their work.
A powerful new illustrated book, What Parkinson’s Feels Like, has been released to help build empathy and raise awareness about the lived experience of Parkinson’s disease. Created by artist Barbara Salsberg Mathews, who was diagnosed with Parkinson’s in 2020, the book translates vivid descriptions from people with Parkinson’s around the world into compelling, mixed-media illustrations.
Parkinson’s disease (PD) is a complex neurodegenerative condition that predominantly affects older people, with a rising prevalence worldwide.1,2 There are many on-going challenges and unmet needs in PD: difficulties in making an accurate diagnosis (particularly in the early stages ...
Parkinson’s disease (PD) is characterized by prodromal and clinical stages; the clinical phase is characterized by a constellation of motor and non-motor symptoms (NMS).1 Despite the extensive discussions and publications of the clinical heterogeneity of PD,2 the precise heterogeneous ...
Parkinson’s disease (PD) is a chronic progressive neurodegenerative disorder characterized by the degeneration of nigrostriatal dopaminergic neurons, with its incidence increasing globally.1 With disease progression, the benefit from medications shortens, and symptom control becomes strictly dependent on peripheral levodopa (...
In modern medicine, the concept of wellness is accompanied by many misconceptions. Adopting wellness as a treatment approach has been well defined and implemented in cardiovascular disease, diabetes and some types of cancer management but has not yet been widely ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
